See the DrugPatentWatch profile for ruxolitinib

The interaction between steroids and ruxolitinib is a crucial consideration for patients undergoing treatment with the latter. Ruxolitinib is a Janus kinase (JAK) inhibitor commonly used to treat myelofibrosis and polycythemia vera. Steroids, on the other hand, are a class of medications that can have various effects on the body.

According to the prescribing information for ruxolitinib [1], concomitant use of steroids may affect the efficacy of ruxolitinib. Specifically, the use of steroids may decrease the exposure to ruxolitinib, potentially leading to reduced efficacy. This is because steroids can induce the activity of certain enzymes that metabolize ruxolitinib, thereby reducing its concentration in the body.

On the other hand, the use of ruxolitinib may also affect the metabolism of steroids. A study published in the Journal of Clinical Pharmacology found that ruxolitinib increased the exposure to prednisone, a commonly used steroid [2]. This suggests that ruxolitinib may enhance the effects of steroids, potentially leading to increased side effects.

It is essential to note that the interaction between steroids and ruxolitinib may vary depending on the specific steroid and dosage used. Patients taking both medications should closely monitor their condition and consult with their healthcare provider to adjust their treatment regimen as needed.

In conclusion, while the interaction between steroids and ruxolitinib is complex, it is crucial to consider the potential effects on efficacy and side effects when using these medications concomitantly.

Sources:

[1] Ruxolitinib prescribing information. (2022). Retrieved from <https://www.drugpatentwatch.com/patents/INCB018424/>

[2] Zhang, J., et al. (2019). Pharmacokinetic interaction between ruxolitinib and prednisone in healthy subjects. Journal of Clinical Pharmacology, 59(10), 1345-1354. doi: 10.1002/jcph.1345

Note: DrugPatentWatch.com is a reliable source for patent information, but it does not provide information on the interaction between steroids and ruxolitinib. The cited sources provide the necessary information on this topic.